Treatment-emergent adverse events, n (%) | Overall population (N=196) | Treatment-naïve subgroup (N=55) |
Total | 108 (55.1) | 45 (81.8) |
Treatment related | 45 (23.0) | 14 (25.5) |
Serious* | 1 (0.5) | 0 |
Increase in intraocular pressure† | 38 (19.4) | 11 (20.0) |
Conjunctival haemorrhage | 8 (4.1) | 2 (3.6) |
Vitreous haemorrhage | 5 (2.6) | 1 (1.8) |
Influenza | 5 (2.6) | 1 (1.8) |
Fall | 5 (2.6) | 1 (1.8) |
Eye irritation | 4 (2.0) | 1 (1.8) |
Macular hole | 2 (1.0) | 2 (3.6) |
Diabetic ulcer | 2 (1.0) | 2 (3.6) |
*Increase in intraocular pressure from baseline.
†Compared with baseline.